SCHEMBL7261663

SCHEMBL7261663

Cc1nc(C=Cc2ccc(Cl)cc2)ccc1CC(=O)O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGDR2 Q9Y5Y4 4/20 0.42
NPC1 O15118 3/20 0.40
RAB9A P51151 3/20 0.40
KDM4E B2RXH2 2/20 0.40
ALDH1A1 P00352 3/20 0.40
HPGD P15428 2/20 0.40
CYP1A2 P05177 2/20 0.40
POLB P06746 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
LMNA P02545 3/20 0.39
MAPT P10636 2/20 0.39
DHFR P00374 1/20 0.39
MEN1 O00255 1/20 0.39
HTT P42858 1/20 0.39
KMT2A Q03164 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
PTGS2 P35354 2/20 0.38
ALOX5 P09917 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7268046 0.85 CYSLTR1 (0.44) KDM4EALDH1A1HPGDCYP1A2CYP2C9
SCHEMBL7268766 0.78 PTGDR2 (0.45) PTGDR2NPC1RAB9AKDM4EALDH1A1
SCHEMBL4710219 0.75 ALOX5 (0.49) NPC1RAB9AKDM4EALDH1A1LMNA
SCHEMBL4710220 0.75 ALOX5 (0.49) NPC1RAB9AKDM4EALDH1A1LMNA
SCHEMBL4715316 0.73 MEN1 (0.51) NPC1RAB9AKDM4EALDH1A1HPGD
SCHEMBL4715315 0.73 MEN1 (0.51) NPC1RAB9AKDM4EALDH1A1HPGD
SCHEMBL10813695 0.70 KDM4E (0.48) PTGDR2NPC1RAB9AKDM4EALDH1A1
SCHEMBL10813700 0.70 KDM4E (0.48) PTGDR2NPC1RAB9AKDM4EALDH1A1
SCHEMBL7266628 0.70 RAB9A (0.54) NPC1RAB9AKDM4EALDH1A1CYP1A2
SCHEMBL27481842 0.69 RAB9A (0.44) NPC1RAB9AKDM4EALDH1A1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6656957-B1 Marked and selective modulating, especially antagonistic, action at human metabotropic glutamate receptors (mGluRs); treatment of disorders such as epilepsy, cerebral ischemias, especially acute ischemias, spasticity etc. NOVARTIS AG (CH) 2003-12-02 US disclosed